Clinical trials: Kawasaki Disease
SARS CoV-2, Kawasaki Disease
Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)
Human Endogenous Retroviruses (HERVs) are ancient sequences that became integrated into our DNA during evolutionary processes. The significance of their presence in DNA is still being studied, but HERVs appear to be involved in…
- Conditions
- SARS CoV-2, Kawasaki Disease, Retrovirus Infection
- Trial name
- HERV_COVID (NCT06775457)
- Testing
- sample collection
- Where
- 5 sites in Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Kawasaki Disease
Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD.
To investigate the safety and long-term vascular remodeling after bioresorbable vascular scaffold (BVS) implantation for stenotic or occluded lesion in children or young adults with Kawasaki disease (KD).
- Trial name
- NCT02771288
- Testing
- Bioresorbable Vascular Scaffold
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Kawasaki Disease, Coronary Artery Aneurysm
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed.
- Trial name
- RIVA-KG (NCT05643651)
- Testing
- Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Fudan University
Kawasaki Disease
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
This study evaluates the efficacy and safety of the addition of Firsekibart to standard initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in children with Acute Kawasaki Disease (KD) .
- Trial name
- NCT07686770
- Testing
- IVIG, Aspirin, Firsekibart
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Children's Hospital of Fudan University
Kawasaki Disease, Pilot Study
Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
Based on a population pharmacokinetic model-based dose optimization study, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after Kawasaki disease was…
- Conditions
- Kawasaki Disease, Pilot Study, Coronary Artery Aneurysm, Rivaroxaban
- Trial name
- NCT06978439
- Testing
- Rivaroxaban (Xarelto)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Fudan University